Remove lillys-jaypirca-blazes-leukemia-trail-fda-nod-fast-confirmatory-trial-filing
article thumbnail

Lilly's Jaypirca blazes leukemia trail with FDA nod, fast confirmatory trial filing

Fierce Pharma

As AbbVie, Johnson & Johnson, AstraZeneca and BeiGene are battling it out in the same BTK inhibitor market, Eli Lilly is trailblazing a new path for the blood cancer drug class. |

FDA 269